Bengaluru, India, February 9, 2026: Pandorum Technologies has raised US$18 million in Series B funding as it moves from research-driven innovation into global clinical execution, strengthening its position in the fast-evolving field of regenerative and exosome-based medicine.
The biotechnology company, which operates across India and the United States, will use the fresh capital to advance late-stage clinical programs, expand manufacturing capacity, and establish a stronger operational footprint in key international markets, including the U.S., Japan, and the Middle East.
The financing round was led by Protons Corporate, with backing from Galentic Pharma, noted public-market investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, the Burman Family, and other strategic investors. The transaction was structured under the guidance of Bandana Kankani, advisor and investor at Pandorum, with a focus on long-term platform scalability and clinical value creation.
From Research Platform to Global Clinical Delivery Pandorum’s Next Big Leap
Founded by Dr. Tuhin Bhowmick and Arun Chandru, Pandorum has developed a proprietary regenerative platform that combines computational design, engineering, and biology to produce tunable exosome therapies capable of reprogramming diseased tissues rather than merely managing symptoms.
The company’s lead therapeutic candidate, Kuragenx, targets severe ocular surface disorders such as Stevens–Johnson Syndrome and Neurotrophic Keratitis, areas with limited treatment options. Kuragenx has already received Orphan Drug Designation from the U.S. Food and Drug Administration, positioning it for accelerated regulatory pathways.
“Human tissues are dynamic systems that continuously rebuild themselves,” said Dr. Tuhin Bhowmick, Co-Founder and CEO of Pandorum Technologies. “Pandorum’s goal is to guide that process by restoring biological signals that drive healing. This investment allows us to move decisively from foundational science into scalable, disease-modifying clinical solutions.”
Pandorum’s clinical programs are supported by an international consortium of specialists, including Dr. Virender Singh Sangwan in India, Dr. Shigeru Kinoshita in Japan, and Dr. Ramez Haddadin and Dr. Satish Nadig in the United States, enabling coordinated multi-geography clinical development.
To support its clinical ambitions, Pandorum has adopted a distributed manufacturing model, partnering with AGC Biologics in Italy for Western markets and Nucelion Therapeutics, a Bharat Biotech subsidiary, to serve Asia-Pacific demand. The company is also evaluating manufacturing and commercial partnerships in the Middle East as part of its next expansion phase.
While ophthalmology remains the primary near-term focus, Pandorum plans to extend its regenerative platform to address systemic inflammatory and degenerative conditions affecting organs such as the lung, liver, and nervous system.
Pandorum Technologies is a biotechnology company developing regenerative and tissue-engineering therapies, with research and development operations in India and the United States.
